Key Points

• US IPO activity generated approximately $813.5 million in announced pricing across three conventional offerings and two SPAC transactions, although OPay’s delayed trading debut leaves part of the reported proceeds unverified.
• European issuance advanced through TEK4 Group’s £24.75 million AIM admission, while the transaction’s substantial secondary component limited the capital flowing directly to the company.
• India became the center of Asian IPO activity as Jio Platforms and Paras Healthcare began trading, with Jio raising approximately ₹30,213 crore and recording a strong first-session performance.

Global IPO Markets Reflect Uneven Capital Allocation

The October 26–30 trading week demonstrated that global IPO activity remained concentrated in selected issuers and markets rather than advancing uniformly. US biotechnology companies accessed public capital, although their initial trading performance was mixed, while a significant AI-related filing expanded the potential US pipeline. Europe recorded a London AIM admission, and India generated substantial activity through the listings of Jio Platforms and Paras Healthcare. Israel recorded no significant IPO activity during the period. Meanwhile, the VIX ended the week at 19.42, approximately 5.6% above its October 26 close, as investors assessed technology valuations, inflation risks, and central-bank policy. These developments reflected a market in which transaction execution and post-listing performance remained important measures of investor demand.

United States — Biotechnology Offerings Meet Selective Trading Demand

Three conventional IPOs and two SPAC offerings priced during the week, representing approximately $813.5 million in announced gross proceeds. Aspen Neuroscience priced at $15 per share, raising approximately $140.6 million, while Bambusa Therapeutics priced at $16, raising approximately $168.9 million. Both biotechnology issuers traded below their offer prices at the displayed closing levels: Aspen at $14.89 and Bambusa at $14.99. OPay announced a $19-per-ADS offering targeting $304 million, but did not begin trading on October 30, leaving the completion of its transaction unverified. BHAV Acquisition II and SPACCircle Acquisition each priced $100 million offerings. The pipeline also expanded with seven filings, including Anthropic, for which Renaissance Capital estimated a potential $75 billion offering. Kepuni Holdings withdrew its proposed $15 million IPO, illustrating continued execution risk.

Europe — AIM Admission Adds Issuance but Limits Primary Capital

TEK4 Group plc joined the London Stock Exchange’s AIM market on October 26 through a placing of 12.375 million shares at 200 pence each. The transaction generated £24.75 million in total proceeds, although only £2 million went directly to the company, with £22.75 million accruing to selling shareholders. The distinction between primary and secondary proceeds is important when assessing the contribution of a listing to corporate financing. The supplied pricing data showed a current price of 330 pence against the 200-pence placing price. Other prospective UK issuers appeared in the market pipeline, but no additional significant completed European exchange listing was confirmed during the week. The region’s activity therefore centered on one AIM admission rather than a broad increase in new issuance across European exchanges.

Asia — Indian Listings Concentrate Regional IPO Activity

India led Asian IPO activity as Jio Platforms and Paras Healthcare began trading on October 28. Jio raised approximately ₹30,213 crore, with its shares opening at ₹1,358 against an issue price of ₹1,119. The stock subsequently closed its first NSE trading session at approximately ₹1,417.50, representing a gain of 26.68% from the issue price. Paras Healthcare listed at ₹720 against an IPO price of ₹693, an initial premium of approximately 3.90%. These debuts gave India a prominent role in the week’s global issuance activity. By contrast, no significant new conventional IPO listing was confirmed in Hong Kong, Japan, mainland China, or Singapore in the reviewed data. The regional picture was therefore driven primarily by Indian offerings rather than a broad expansion across Asian exchanges.

Israel — No Significant IPO Activity

No significant IPO activity was confirmed in Israel during October 26–30. The weekly data did not identify a material new Israeli IPO pricing, market debut, or announced offering that would indicate a change in domestic issuance momentum. The absence of a confirmed transaction should not be interpreted as evidence that companies were not preparing potential listings privately. However, without a verified prospectus, pricing announcement, or exchange admission, there was insufficient evidence to identify a significant development in the Israeli IPO market. Israel consequently contributed no material confirmed transaction to the period’s regional listing activity.

Next Session — Monitor IPO Pipeline Execution and Central-Bank Signals

The next trading week will test whether recently filed US issuers advance toward pricing and whether biotechnology companies can stabilize after their initial market debuts. Investors will also monitor OPay for clarification of its delayed trading status and Anthropic for further developments concerning its proposed offering. In Asia, follow-through in Jio Platforms and other Indian listings will provide additional evidence of demand. The VIX, Federal Reserve guidance, and Bank of Japan policy signals will remain relevant to valuation expectations and the capacity of markets to absorb new issuance.